Clinical Outcomes: Abstracts

AVITA MEDICAL IS LEADING THE WAY AND ADVANCING CARE FOR BURN PATIENTS

Abstracts, Posters and Presentations

Extensive research has been conducted and distributed for public review. Below is a snapshot of abstracts with a focus on burn injuries.

Title Presenter Conference
Two State-Of-The-Art-Surgical Techniques for the Treatment of Deep Second Degree Burns Eberwein 2021 Joseph M. Still Burn Symposium
Financial Impact of Autologous Skin Cell Suspension into Standard of Care Practice Kopari 2021 North American Burn Society
Combining Two State-Of-The-Art-Surgical Techniques for the Treatment of Deep Second Degree Burns. North American Burn Society Eberwein 2021 North American Burn Society
A Novel Combined Approach to Enzymatic Debridement and Autologous Skin Cell Suspension: A Case Report Litner 2021 North American Burn Society
Autologous Skin Cell Suspension (ASCS) for the Treatment of Small (<10% TBSA) Mixed-Depth Burn. American Burn Association Carter 2021 North American Burn Society
Evaluating Real-World National and Regional Trends in Definitive Closure in US Burn Care: A Survey of US Burn Centers Carter 2021 North American Burn Society
Cost-effectiveness of Autologous Cell Harvesting Device for the Treatment of Burns Requiring Hospitalization: An Economic Evaluation using Real World Data. American Burn Association. Virtual. 2021 April 7-9. Carter 2021 North American Burn Society
Utilizing Simulation Based Training to Teach Wound Management Strategies When Caring for Burns Treated with ASCS Johnson 2021 North American Burn Society
How A Recurring Problem Prompted The Combination Of Technologies. Our Institutional Experience With The Simultaneous Application Of Poly Lactic Acid Polymer Dressings After Application Of Suspension Epidermal Autografts Short 2021 North American Burn Society
A Real World Economic Evaluation of the Cost-effectiveness of Autologous Cell Harvesting Device for the Treatment of Burns Requiring Hospitalization Hickerson 2021 Boswick Burn and Wound Care Symposium
Implementing Autologous Skin Cell Suspension at an ABA Burn Center: A Comparison of Operative Efficiency Using RECELL Versus Standard Split Thickness Autografting Skibba 2021 Boswick Burn and Wound Care Symposium
RITA: A Simulation Based Training Prograf to Replicate Real-Life Wound Care Experiences in Burns Treated with Autologous Skin Cell Suspension Bell 2021 Boswick Burn and Wound Care Symposium
The Faces of Autologous Skin Cell Suspension as Epidermal Grafts Kopari 2020 American Burn Association
Real World Treatment Trends for Patients TBSA ≤ 20%: Evaluating Important Shifts in Care and Budget Impact of ASCS Adoption Holmes 2020 American Burn Association
Regenerative Burn Surgery – evolution of an innovative concept with enzymatic debridement and in situ autologous cell and platelet-rich fibrin therapy M Waldner 2019 European Burns Association
Budget impact of autologous cell harvesting device (ACHD) use versus standard of care (SOC) for treatment of severe burns: A case study for the Arizona Burn Center K Foster 2019 American Burn Association
Combining RECELL® with Meshed Autografts Reduces Donor Skin Requirements for the Treatment of Full-Thickness Burn Wounds J Carter 2019 Boswick Burn and Wound Care Symposium
A Comparative Study of Autologous Skin Cell Suspension to Split-thickness Skin Grafts in the Treatment of Deep Partial-thickness Acute Burn Wounds W Hickerson 2019 Boswick Burn and Wound Care Symposium
Establishing the Safety and Efficacy of ReCell™ as an Autograft Sparing Technology for Definitive Closure of Burn Injuries J Holmes 2019 North American Burn Society
Establishing the Safety and Effectiveness of RECELL® as an Autograft-sparing Technology for Definitive Closure of Burn Injuries J Holmes 2018 Southern Region Burn Conference
Establishing the Safety and Effectiveness of RECELL® as an Autologous Autograft-sparing Technology for Definitive Wound Closure of Burn Injuries J Shupp 2018 Northeast Region Burn Conference
Establishing the Effectiveness of RECELL® as an Autograft-Sparing Technology for Definitive Closure of Burn Injuries J Carter 2018 Midwest Region Burn Conference
Establishing the Safety and Effectiveness of RECELL® as an Autograft-sparing Technology for Definitive Closure of Burn Injuries Carter 2018 Eastern Great Lakes Region Burn Conference
Establishing the Safety and Effectiveness of RECELL® as an Autograft-sparing Technology for Definitive Closure of Burn Injuries J Holmes 2018 Military Health System Research Symposium
Cost-effectiveness of an Autologous Regenerative Epithelial Suspension versus Standard of Care for Treatment of Severe Burns in the United States K Foster 2018 American Burn Association
Demonstration of the Safety and Effectiveness of Autologous Skin Cell Suspension Combined with Meshed Skin Grafts for the Reduction of Donor Area in the Treatment of Acute Burns J Holmes 2018 American Burn Association
A Comparative Study of Autologus Skin Cell Suspension to Split-thickness Autografting in the Treatment of Acute Burns (ReCell-5) W Hickerson 2018 American Burn Association
Accelerated wound healing in enzymatically debrided, deep-scale burns by applying a spraying method of autologous keratinocytes Kuepper 2017 35th Annual Meeting of the German-speaking Working Group for Burn Treatment (DAV)
Establishing the Effectiveness of RECELL® as an Autograft-Sparing Technology for Definitive Closure of Burn Injuries J Carter 2017 Chinese Burns Association
RECELL® and Regenerative Epithelial Suspension (RES) J Shupp 2017 Northeast Region Burn Conference
RECELL®: An Effective Device for the Treatment of Acute Burn Injuries W Hickerson 2017 European Burns Association
Establishing the Effectiveness of RECELL® as an Autograft-sparing Technology for Definitive Closure of Burn Injuries J Holmes 2017 European Burns Association

For additional information, please review our Abstract and Publications libraries.

PATIENT OUTCOMES

AVITA icons abstracts

ABSTRACTS

AVITA icons publications

PUBLICATIONS

AVITA icons videos

VIDEOS

AVITA icons abstracts

HEALTH ECONOMICS

IMPORTANT SAFETY INFORMATION (United States)

INDICATIONS FOR USE: The RECELL® Autologous Cell Harvesting Device is indicated for the treatment of acute thermal burn wounds. The RECELL® device is used by an appropriately-licensed healthcare professional at the patient’s point of care to prepare autologous RES® Regenerative Epidermal Suspension for direct application to acute partial-thickness thermal burn wounds in patients 18 years of age and older or application in combination with meshed autografting for acute full-thickness thermal burn wounds in pediatric and adult patients.

CONTRAINDICATIONS: RECELL® is contraindicated for: the treatment of wounds clinically diagnosed as infected or with necrotic tissue, the treatment of patients with a known hypersensitivity to trypsin or compound sodium lactate (Hartmann’s) solution, patients having a known hypersensitivity to anesthetics, adrenaline/epinephrine, povidone-iodine, or chlorhexidine solutions.

WARNINGS AND PRECAUTIONS: Autologous use only. Wound beds treated with a cytotoxic agent (e.g., silver sulfadiazine) should be rinsed prior to application of the cell suspension. RECELL® is provided sterile and is intended for single-use. Do not use if packaging is damaged or expired. Choose a donor site with no evidence of cellulitis or infection and process skin immediately. A skin sample should require between 15 and 30 minutes contact with Enzyme. Contact in excess of 60 minutes is not recommended. RECELL® Enzyme is animal derived and freedom from infectious agents cannot be guaranteed.

PRECAUTIONS: RECELL® is not intended for use without meshed autograft for treatment of full-thickness burn wounds. The safety and effectiveness of RECELL® without meshed autograft have not been established for treatment of partial-thickness burn wounds: on the hands and articulating joints, >320 cm2, in patients with wounds totaling >20% total body surface area (TBSA). The safety and effectiveness of RECELL with autografting have not been established for treatment of full-thickness burn wounds: on the hands and articulated joints, and in patients younger than 28 days of age (neonates).

SPECIAL PATIENT POPULATIONS: The safety and effectiveness of RECELL® have not been established for treatment of acute thermal partial-thickness burn wounds in pediatric patients younger than 18 years of age.

For complete Important Safety Information, refer to Instructions For Use. Please be aware that any indication for RECELL® outside of the United States may differ from the US indication. Please see the Instructions for Use for each country for the specific indication of RECELL®.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to AVITA, its subsidiaries or affiliates. No use of any AVITA trademark, trade name, or trade dress in this site may be made without the prior written authorization of AVITA, except to identify the product or services of the company.
©Copyright 2022 AVITA Medical. All Rights Reserved.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to AVITA, its subsidiaries or affiliates. No use of any AVITA trademark, trade name, or trade dress in this site may be made without the prior written authorization of AVITA, except to identify the product or services of the company.
©Copyright 2022 AVITA Medical. All Rights Reserved.